[go: up one dir, main page]

MX2018011813A - Medicina obtenida mediante la combinacion de agonista fxr y arb. - Google Patents

Medicina obtenida mediante la combinacion de agonista fxr y arb.

Info

Publication number
MX2018011813A
MX2018011813A MX2018011813A MX2018011813A MX2018011813A MX 2018011813 A MX2018011813 A MX 2018011813A MX 2018011813 A MX2018011813 A MX 2018011813A MX 2018011813 A MX2018011813 A MX 2018011813A MX 2018011813 A MX2018011813 A MX 2018011813A
Authority
MX
Mexico
Prior art keywords
arb
combining
fxr agonist
medicine obtained
pharmaceutically acceptable
Prior art date
Application number
MX2018011813A
Other languages
English (en)
Inventor
Namisaki Tadashi
Yoshiji Hitoshi
Original Assignee
Intercept Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intercept Pharmaceuticals Inc filed Critical Intercept Pharmaceuticals Inc
Publication of MX2018011813A publication Critical patent/MX2018011813A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invención proporciona un agente terapéutico para NASH que incluye: un agonista de FXR, preferiblemente ácido obeticólico o una sal farmacéuticamente aceptable del mismo; y un ARB o una sal farmacéuticamente aceptable del mismo.
MX2018011813A 2016-03-28 2017-03-27 Medicina obtenida mediante la combinacion de agonista fxr y arb. MX2018011813A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2016064475 2016-03-28
PCT/JP2017/012448 WO2017170434A1 (ja) 2016-03-28 2017-03-27 Ｆｘｒアゴニストとａｒｂの組み合わせ医薬

Publications (1)

Publication Number Publication Date
MX2018011813A true MX2018011813A (es) 2019-01-24

Family

ID=59965591

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018011813A MX2018011813A (es) 2016-03-28 2017-03-27 Medicina obtenida mediante la combinacion de agonista fxr y arb.

Country Status (17)

Country Link
US (1) US11419878B2 (es)
EP (1) EP3437659B1 (es)
JP (1) JPWO2017170434A1 (es)
KR (1) KR20180124123A (es)
CN (1) CN109152840A (es)
AU (1) AU2017241559A1 (es)
BR (1) BR112018069789A2 (es)
CA (1) CA3019496A1 (es)
CL (1) CL2018002727A1 (es)
EA (1) EA037330B1 (es)
IL (1) IL262057A (es)
MX (1) MX2018011813A (es)
PH (1) PH12018502109A1 (es)
SG (1) SG11201808607SA (es)
TW (1) TW201733582A (es)
UA (1) UA124499C2 (es)
WO (1) WO2017170434A1 (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2021002305A (es) * 2018-08-30 2021-05-31 Terns Pharmaceuticals Inc Tratamiento de trastornos del higado.
MX2021005316A (es) * 2018-11-08 2021-09-10 Intercept Pharmaceuticals Inc Métodos de uso del ácido obeticólico.
CN121081472A (zh) 2018-12-13 2025-12-09 拓臻股份有限公司 一种THRβ受体激动剂化合物及其制备方法和用途
DE102019108825A1 (de) * 2019-04-04 2020-10-08 Eberhard Karls Universität Tübingen Medizinische Fakultät Verbindungen und Verfahren zur Behandlung von Erkrankungen der Leber
KR20210020788A (ko) 2019-08-14 2021-02-24 주식회사 바이오톡스텍 하이드로퀴논 유도체, 및 오베티콜릭산을 포함하는 비알콜성 지방간염의 예방 또는 치료용 약학조성물
AU2020336272A1 (en) 2019-08-23 2022-04-14 Terns Pharmaceuticals, Inc. Thyroid hormone receptor beta agonist compounds
EP4028008A4 (en) 2019-09-12 2023-09-13 Terns Pharmaceuticals, Inc. Thyroid hormone receptor beta agonist compounds
CN114667142A (zh) * 2019-11-08 2022-06-24 拓臻制药公司 治疗肝脏病症
US20220387414A1 (en) * 2019-11-08 2022-12-08 Terns Pharmaceuticals Inc. Treating liver disorders
EP4069306A1 (en) * 2019-12-04 2022-10-12 Ashvattha Therapeutics, Inc. Triantennary n-acetylgalactosamine modified hydroxyl polyamidoamine dendrimers and methods of use thereof
US20230105984A1 (en) * 2019-12-23 2023-04-06 Svetlana Marukian Compositions and methods for the treatment of liver diseases and disorders
KR20230023642A (ko) * 2020-05-13 2023-02-17 테른스 파마슈티칼스, 인크. 간 장애의 조합 치료
EP4204405A4 (en) 2020-08-25 2024-05-29 Eli Lilly and Company POLYMORPHS OF AN SSAO INHIBITOR
WO2022056238A1 (en) * 2020-09-11 2022-03-17 Terns Pharmaceuticals, Inc. Solid dispersion formulations of an fxr agonist
JP2023547597A (ja) * 2020-10-15 2023-11-13 イーライ リリー アンド カンパニー Ｆｘｒアゴニストの多形
WO2023048526A1 (ko) 2021-09-24 2023-03-30 (주)샤페론 염증복합체 억제제를 유효성분으로 함유하는, 비알코올성 지방간염, 간 섬유화의 예방, 개선 또는 치료용 약학적 조성물
KR20230052237A (ko) 2021-10-12 2023-04-19 (주)샤페론 타우로데옥시콜산 신규 제제
JPWO2023140350A1 (es) * 2022-01-21 2023-07-27
WO2024136627A1 (ko) * 2022-12-20 2024-06-27 주식회사 티에치팜 나트륨 포도당 운반체-2 저해제 및 안지오텐신 ⅱ 수용체 차단제를 함유하는 비알코올성 지방간 질환 예방 또는 치료용 약학적 조성물
CN117838692A (zh) * 2023-11-17 2024-04-09 上海交通大学医学院附属新华医院 NR1H4激动剂Tropifexor在小儿短肠综合征肠道代偿治疗中的应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7138390B2 (en) 2001-03-12 2006-11-21 Intercept Pharmaceuticals Steroids as agonists for FXR
SI1734970T1 (sl) 2004-03-12 2015-04-30 Intercept Pharmaceuticals, Inc. Zdravljenje fibroze z uporabo FXR ligandov
WO2008002573A2 (en) 2006-06-27 2008-01-03 Intercept Pharmaceuticals, Inc. Bile acid derivatives as fxr ligands for the prevention or treatment of fxr-mediated deseases or conditions
TW200906823A (en) 2007-07-16 2009-02-16 Lilly Co Eli Compounds and methods for modulating FXR
PE20100156A1 (es) * 2008-06-03 2010-02-23 Boehringer Ingelheim Int Tratamiento de nafld
EP2289883A1 (en) 2009-08-19 2011-03-02 Phenex Pharmaceuticals AG Novel FXR (NR1H4) binding and activity modulating compounds
SG11201408501UA (en) * 2012-06-19 2015-01-29 Intercept Pharmaceuticals Inc Preparation, uses and solid forms of obeticholic acid
AU2014230096C1 (en) * 2013-03-15 2019-08-29 Boehringer Ingelheim International Gmbh Use of linagliptin in cardio- and renoprotective antidiabetic therapy
AU2014230444B2 (en) * 2013-03-15 2018-05-17 Mochida Pharmaceutical Co., Ltd. Compositions and methods for treating non-alcoholic steatohepatitis
CA2914924A1 (en) * 2013-06-13 2014-12-18 Fast Forward Pharmaceuticals B.V. Cd40 signalling inhibitor and a further compound, wherein the further compound is a bile acid, a bile acid derivative, an tgr5-receptor agonist, an fxr agonist or a combination thereof, for the treatment of chronic inflammation, and the prevention of gastrointestinal cancer or fibrosis.
ES2817527T3 (es) * 2013-07-18 2021-04-07 Mochida Pharm Co Ltd Composición autoemulsionante de ácidos grasos omega-3
CN105175473B (zh) * 2015-08-19 2018-12-21 丽珠医药集团股份有限公司 一种奥贝胆酸晶型i及其制备方法、药物组合物和用途

Also Published As

Publication number Publication date
CL2018002727A1 (es) 2018-12-07
KR20180124123A (ko) 2018-11-20
BR112018069789A2 (pt) 2019-01-29
UA124499C2 (uk) 2021-09-29
EA201892119A1 (ru) 2019-02-28
CA3019496A1 (en) 2017-10-05
TW201733582A (zh) 2017-10-01
IL262057A (en) 2018-11-29
EP3437659A4 (en) 2019-12-11
WO2017170434A1 (ja) 2017-10-05
SG11201808607SA (en) 2018-11-29
EP3437659A1 (en) 2019-02-06
AU2017241559A1 (en) 2018-11-01
US11419878B2 (en) 2022-08-23
EP3437659B1 (en) 2023-03-01
JPWO2017170434A1 (ja) 2019-01-31
PH12018502109A1 (en) 2019-09-23
EA037330B1 (ru) 2021-03-12
US20190247404A1 (en) 2019-08-15
CN109152840A (zh) 2019-01-04

Similar Documents

Publication Publication Date Title
PH12018502109A1 (en) Medicine obtained by combining fxr agonist and arb
MX2024004439A (es) Agentes terapeuticos para enfermedades neurodegenerativas
MX2016012574A (es) Compuestos heteroarilo sustituidos y metodos de uso.
MY199027A (en) Method for treating or preventing ophthalmological conditions
JOP20200230A1 (ar) ناهضات ppar (مستقبل ناشر بيروكسيزوم منشط)، ومركبات، ومكونات أدوية، وطرق استعمالها
CY1124251T1 (el) Παραγωγα καρβοξαμιδιου
MX2015010829A (es) Compuestos terapeuticos y sus usos.
PH12016501841A1 (en) Immunosuppressant formulation
MA39765A (fr) Formulation pharmaceutique d'un inhibiteur de la kinase pan-raf, ses procédés de préparation, et procédés d'utilisation
WO2015171558A3 (en) BENZENESULFONAMIDO AND RELATED COMPOUNDS FOR USE AS AGONISTS OF RORγ AND THE TREATEMENT OF DISEASE
MX2016011105A (es) Inhibidores de monoacilglicerol aciltransferasa 2 (mgat2) de dihidropiridinona para usarse en el tratamiento de trastornos metabolicos.
MX2020012989A (es) Agente terapeutico para la fibrosis.
ZA202200511B (en) Ring-fused thiazolino 2-pyridones, methods for preparation thereof and their use in the treatment and/or prevention of tuberculosis
MX2016014946A (es) Derivados de carboxamida.
PH12016502233A1 (en) (s)-pirlindole or its pharmaceutically acceptable salts for use in medicine
NZ732704A (en) Quinoline carboxamides for use in the treatment of leukemia
MX2019002901A (es) Tratamiento de esclerosis multiple con chs-131.
CY1119522T1 (el) (r)- πιρλινδολη και τα φαρμακευτικως αποδεκτα αλατα αυτης για χρηση στην ιατρικη
EA201501130A1 (ru) Офтальмологическая фармацевтическая композиция
IN2014MU00043A (es)
EA038580B9 (ru) Агонист fxr, представляющий собой производное стероидов
IN2014DE00822A (es)
PH12016502247A1 (en) Carboxamide derivatives
MX2018002193A (es) Metodo de uso de quinoxalinilo-piperazinamida.